Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma by Takuya Suyama, Kumiko Matsui, Kosuke Makihara, Masatoshi Tsuru

“…Human immunodeficiency virus (HIV)-associated lymphoma poses a high mortality risk despite antiretroviral therapy (ART). …”
Get full text

A Unique Case of Malignant Pleuropericardial Effusion: HHV-8-Unrelated PEL-Like Lymphoma—A Case Report and Review of the Literature by Farhan Mohammad, Muhammad Neaman Siddique, Faraz Siddiqui, M. Popalzai, Masoud Asgari, Marcel Odaimi

“…Primary effusion lymphoma (PEL) or body cavity lymphoma is a rare type of extra nodal lymphoma of B-cell origin that presents as lymphomatous effusion(s) without any nodal enlargement or tumor masses. …”
Get full text

Concurrent B Cell Acute Lymphoblastic Lymphoma/Leukemia and Monoclonal B Cell Lymphocytosis: A Case Report with Extensive Molecular Analysis by Maryam Mehdipour Dalivand, Parastou Tizro, Julie Partain, Anita Aggarwal, Jack Lichy, Francisco Mot Ara, Victor E. Nava

Get full text

Understanding the Molecular Mechanisms of Incomptine A in Treating Non-Hodgkin Lymphoma Associated with U-937 Cells: Bioinformatics Approaches, Part I by Fernando Calzada, Normand García-Hernández, Elihú Bautista, José Manuel Sánchez-López, Miguel Valdes, Claudia Velázquez, Elizabeth Barbosa

Subjects: Get full text

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature by Matthew Lee, Beth A. Martin, Haifaa Abdulhaq

“…Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. …”
Get full text

Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation by Michela Staderini, Lara Mannelli, Elisabetta Antonioli, Benedetta Puccini, Valentina Berti, Francesco Mungai, Federica Vergoni, Valentina Carrai, Luigi Rigacci, Alberto Bosi

“…ALK-negative anaplastic large cell lymphoma is a rare T-cell neoplasm with an aggressive course requiring prompt diagnostic work-up and treatment. …”
Get full text

Survival and prognostic factors for primary lung extranodal NK/T-cell lymphoma: a retrospective study of data from China and the SEER database by Qiuyu Li, Haoyu Zuo, Chengyang Liu, Jing Yang, Nini Dai

Subjects: “…extranodal NK/T-cell lymphoma…”
Get full text

Cavitating Mesenteric Lymph Node Syndrome in Association with Coeliac Disease and Enteropathy Associated T-Cell Lymphoma: A Case Report and Review of the Literature by Olivia M. B. McBride, Richard J. E. Skipworth, Derek Leitch, Satheesh Yalamarthi

“…This is associated with serious complications such as enteropathy-associated T-cell lymphoma (EATL). We present the case of a 71-year-old female investigated for weight loss and a palpable intraabdominal mass. …”
Get full text

Gingival Anaplastic Large-Cell Lymphoma Mimicking Hyperplastic Benignancy as the First Clinical Manifestation of AIDS: A Case Report and Review of the Literature by Rafaela Elvira Rozza-de-Menezes, Stefânia Jeronimo Ferreira, Diogo Lenzi Capella, Stephan Schwartz, Ana Helena Willrich, Lúcia de Noronha, Aline Cristina Batista Rodrigues Johann, Paulo Henrique Couto Souza

“…Oral anaplastic large-cell lymphoma (ALCL) is a rare disorder. Only 5 cases involving the gingiva have been reported, and to our knowledge, this is the first case reported of the ALCL, which mimicked a hyperplastic benignancy as the first clinical manifestation of AIDS.…”
Get full text

MicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B‐Cell Lymphoma: A Systematic Review and Meta‐Analysis by Shaghayegh Khanmohammadi, Mahdi Masrour, Parisa Fallahtafti, Fatemeh Hasani

Subjects: “…diffuse large B‐cell lymphoma…”
Get full text

Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma by Weilong Zhang, Bangquan Ye, Yang Song, Ping Yang, Wenzhe Si, Hairong Jing, Fan Yang, Dan Yuan, Zhihong Wu, Jiahao Lyu, Kang Peng, Xu Zhang, Lingli Wang, Yan Li, Yan Liu, Chaoling Wu, Xiaoyu Hao, Yuqi Zhang, Wenxin Qi, Jing Wang, Fei Dong, Zijian Zhao, Hongmei Jing, Yanzhao Li

“…The COMOS was tested on 214 plasma samples of diffuse large B‐cell lymphoma (DLBCL) and matched healthy controls. Results For early diagnosis, COMOS improved the area under the curve (AUC) value to .993 compared with the individual omics model, with a sensitivity of 95% at 98% specificity. …”
Get full text

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients by Kamel Ait-Tahar, Amanda P. Anderson, Martin Barnardo, Graham P. Collins, Chris S. R. Hatton, Alison H. Banham, Karen Pulford

“…Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. …”
Get full text

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece by George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba

“…Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK-positive NSCLC previously treated with at least one second-generation ALK tyrosine kinase inhibitor. …”
Get full text

Unusual symptoms reveal a rare splenic lymphoma: a case report of PS-DLBCL with neck and shoulder pain as the initial presentation by Shifu Hu, Yuanyuan Hao, Xiangyu Liu, Hanbo Liu

Subjects: “…primary splenic diffuse large B-cell lymphoma…”
Get full text

Evaluating biomarkers in canine cytotoxic interface dermatitis reactions to account for clinical and histopathological similarities and differences by Shriya Kannan, Neil B. Wong, Grace E. Ryan, Nia E. R. James, Ayodeji Ajayi, Janet E. Lubov, Clement N. David, Linda Wrijil, Nicholas A. Robinson, Kelly Hughes, Ramon M. Almela, Jillian M. Richmond

Subjects: Get full text

HLA Class II Defects in Burkitt Lymphoma: Bryostatin-1-Induced 17 kDa Protein Restores CD4+ T-Cell Recognition by Azim Hossain, Jason M. God, Faisal F. Y. Radwan, Shereen Amria, Dan Zhao, Jennifer R. Bethard, Azizul Haque

“…While the defects in HLA class I-mediated Ag presentation by Burkitt lymphoma (BL) have been well documented, CD4+ T-cells are also poorly stimulated by HLA class II Ag presentation, and the reasons underlying this defect(s) have not yet been fully resolved. …”
Get full text

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis by Hongbin Lu, Lulu Luo, Jie Mi, Min Sun, Huaping Wang, Zheng Wang, Wenwen Ding

“…BackgroundThe significance of soluble programmed death protein ligand-1 (PD-L1) in predicting the prognosis of diffuse large B-cell lymphoma (DLBCL) has been previously analyzed, but with conflicting results. …”
Get full text

A Unique “Composite” PTLD with Diffuse Large B-Cell and T/Anaplastic Large Cell Lymphoma Components Occurring 17 Years after Transplant by Kristin La Fortune, Dahua Zhang, Gordana Raca, Erik A. Ranheim

“…Posttransplant lymphoproliferative disorder (PTLD) comprises a spectrum ranging from polyclonal hyperplasia to aggressive monoclonal lymphomas. The majority of PTLDs are of B-cell origin while T-cell PTLDs and Hodgkin lymphoma-like PTLDs are uncommon. …”
Get full text

Successful Vaginal Delivery after Induction of Labour in a Patient Treated for Non-Hodgkin’s Lymphoma of the Cervix: A Case Report and Literature Review by Paola Quaresima, Gabriele Saccone, Valeria Zuccalà, Giuseppe Guarascio, Livio Leo, Giuseppina Amendola, Fulvio Zullo, Michele Morelli, Roberta Venturella

“…Primary non-Hodgkin’s lymphomas of the cervix are rare; they represent about 1% of all cases. …”
Get full text

Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymphoma by Danilo Di Maio, S. A. Mitchell, S. Batson, E. Keeney, Howard H. Z. Thom

“…As a case study, we compared mosunetuzumab versus rituximab/bendamustine, as a proxy for rituximab/chemotherapy, in 3L+ relapsed/refractory follicular lymphoma. Individual patient data for mosunetuzumab (NCT02500407) and a combination of two rituximab/bendamustine 3L+ follicular lymphoma cohorts (NCT02187861/NCT02257567) were used. …”
Get full text